.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ sophisticated bosom cancer cells and active or even secure brain metastases revealed constant intracranial task as well as wide spread efficiency of T-DXd.